Financial releases

Safe, fast and effective use of ZENEO® Midazolam validated by a new human factors study in the United States

Great success of the exercise of warrants

ZENEO® Midazolam clinical study: completion of the injection phase

Agreement with BARDA on ZENEO® Midazolam

First injections of ZENEO® Midazolam for the clinical bioequivalence study

2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023

Conformity of the first industrial transposition batch of Zeneo® Hydrocortisone

Crossject strengthens its financial resources and gives all shareholders an interest in the 2022 outlook through a free allocation of equity warrants

Validation of the ZENEO® Midazolam clinical batch

Good Manufacturing Practices certificate issued by the ANSM